What diagnosis and treatment are indicated for a skin biopsy showing psoriasiform epidermal hyperplasia, spongiosis, and scattered eosinophils?

Diagnosis: Spongiotic Psoriasiform Dermatitis with Eosinophils

This biopsy pattern represents a hybrid inflammatory dermatosis with overlapping features of psoriasis and eczema, requiring treatment that targets both Th17 and Th2 immune pathways—JAK inhibitors are the most effective therapeutic option for this specific histopathologic presentation 1.

Understanding the Pathology

The combination of psoriasiform epidermal hyperplasia, spongiosis, and scattered eosinophils creates a diagnostic challenge because it doesn't fit cleanly into classical psoriasis or eczema categories. Recent evidence demonstrates this represents a distinct immunophenotype:

• Dual immune activation: Both Th17 pathways (typical of psoriasis) and Th2 pathways (typical of eczema) are simultaneously activated 1
• Eosinophils in psoriasis are common: Present in approximately 46% of psoriasis cases, with 1-5 eosinophils found in 24% and >5 eosinophils in 26% of cases 2, 3
• Spongiosis correlation: Eosinophils appear only in psoriatic lesions that also show spongiosis 3

The presence of eosinophils should NOT exclude psoriasis from your differential diagnosis, but when combined with spongiosis, it signals this hybrid pattern 3.

Critical Differential Diagnoses to Exclude

Before finalizing treatment, rule out these conditions:

1. Drug-Induced Dermatitis

• Immune checkpoint inhibitor (ICI) toxicity: If the patient is on nivolumab, pembrolizumab, or other ICIs, this exact histologic pattern (psoriasiform + spongiotic + eosinophils) is a recognized immune-related adverse event 4, 5
• Other drug reactions: DRESS syndrome or severe drug eruptions can present similarly 6

2. Eosinophilic Esophagitis (if GI symptoms present)

• While primarily esophageal, systemic eosinophilia with cutaneous involvement requires consideration 7, 8
• Check for dysphagia, food impaction, or reflux symptoms
• Peak eosinophil count >15/HPF in esophageal biopsies confirms diagnosis 8

3. Hypereosinophilic Syndrome

• Requires peripheral blood eosinophilia with end-organ damage 9
• Check complete blood count with differential
• Look for cardiac, pulmonary, or neurologic involvement

Treatment Algorithm

First-Line: JAK Inhibitors

JAK inhibitors are superior to single-pathway biologics for this specific histopathologic pattern because they simultaneously suppress both Th17 and Th2 inflammatory cascades and block epidermal hyperproliferation 1.

Evidence basis: Patients with this hybrid pattern show poor response or disease exacerbation with IL-17A inhibitors (pure Th17 blockade) but achieve significant clinical improvement with JAK inhibition 1.

Practical approach:

• Oral JAK inhibitors (upadacitinib, abrocitinib) or topical ruxolitinib
• Expect response within 4-8 weeks
• Monitor CBC, liver function, lipids per standard JAK inhibitor protocols

Second-Line Options (if JAK inhibitors contraindicated)

1. High-potency topical corticosteroids

   • Clobetasol 0.05% or fluocinonide 0.05% (cream/ointment) 4
   • Apply twice daily to affected areas
   • Taper over 3 weeks once symptoms improve to Grade 1 4

2. Topical calcineurin inhibitors

   • Tacrolimus 0.1% ointment for sensitive areas 4

3. Systemic corticosteroids (for severe/extensive disease)

   • Prednisone 0.5-1 mg/kg/day
   • Taper based on clinical response
   • Bridge to steroid-sparing agent

Avoid These Treatments

• IL-17A inhibitors alone (ixekizumab, secukinumab): May cause disease exacerbation in this phenotype 1
• Pure Th2 inhibitors alone (dupilumab): Insufficient for the Th17 component
• TNF inhibitors: Not specifically effective for this hybrid pattern 8

Common Pitfalls

1. Misdiagnosing as pure psoriasis: The spongiosis and eosinophils signal dual pathology—treating with IL-17 inhibitors alone can worsen the condition 1

2. Dismissing eosinophils as "ruling out psoriasis": This outdated dogma ignores current evidence showing eosinophils in nearly half of psoriasis cases 2, 3

3. Missing drug-induced etiology: Always obtain medication history, especially for ICIs, before initiating immunosuppression 4, 5

4. Undertreating with topicals alone: If body surface area >10% or quality of life significantly impaired, systemic therapy is warranted

Monitoring and Follow-Up

• Clinical assessment: Every 4-8 weeks initially
• Repeat biopsy: Only if treatment fails or clinical presentation changes dramatically
• Laboratory monitoring:
  • Baseline and periodic CBC (for JAK inhibitors or systemic immunosuppression)
  • Peripheral eosinophil count if systemic eosinophilia suspected
  • Liver and renal function with systemic agents

When to Refer

• Dermatology: All cases for treatment initiation and management
• Allergy/Immunology: If systemic eosinophilia (absolute eosinophil count >1500/μL) or suspected hypereosinophilic syndrome 9
• Oncology: If patient on immune checkpoint inhibitors 4